Mucoactive cough therapy: what is behind the horizon?
Abstract
General therapeutic approaches to management of patients with cough were discussed, drug methods of treatment of patients with cough were considered, with special emphasize on mucoactive preparations.
References
1. Morice A. Epidemiology of cough // Pulm Pharmacol Ther. 2002; 15: 253–259.
2. Morice A., McGarvey L., Pavord I. et al. Recommendations for the management of cough in adults // Thorax. 2006; 61: 1–24.
3. Чучалин А. Г., Амбросимов В. Н. Кашель. М.: Изд. «Эхо», 2012. 128 с.
4. Зайцев А. А., Оковитый С. В. Кашель: дифференциальный диагноз и рациональная фармакотерапия // Терапевтический архив. 2014. Т. 86. № 12. С. 85–91.
5. Cullinan P. Persistent cough and sputum: prevalence and clinical characteristics in south east England // Respir Med. 1992; 86: 143–149.
6. Lundback B., Nystrom L., Rosenhall L. et al. Obstructive lung disease in northern Sweden: respiratory symptoms assessed in a postal survey // Eur Respir J. 1991; 4: 257–266.
7. Cerveri I., Accordini S., Corsico A. et al. Chronic cough and phlegm in young adults // Eur Respir J. 2003; 22 (3): 413–417.
8. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Доступно на http://goldcopd.org/gold-reports/.
9. Fuhrman C., Delmas M. Epidemiology of chronic obstructive pulmonary disease in France // Rev Mal Respir. 2010; 27 (2): 160–168.
10. Buist A. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study // Lancet. 2007; 370 (9589): 741–750.
11. Menezes A. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study // Lancet. 2005; 366 (9500): 1875–1881.
12. Chuchalin A., Khaltaev N., Аntonov N. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation // Int J COPD. 2014; 9: 963–974.
13. Зайцев А. А., Оковитый С. В., Крюков Е. В. Кашель. Практическое пособие для врачей. М.: Главный военный клинический госпиталь им. Н. Н. Бурденко, 2015.
14. Зайцев А. А. Направления фармакотерапии и профилактики острых респираторных вирусных инфекций // РМЖ. 2009; Т. 17. № 23: 1525–1529.
15. Зайцев А. А., Синопальников А. И. Рациональная фармакотерапия острых респираторных вирусных инфекций // Consilium Medicum. 2008; Т. 10. № 10: 80–86.
16. Оковитый С. В., Анисимова Н. А. Фармакологические подходы к противокашлевой терапии // Русский медицинский журнал. 2011; № 23: 1150–1158.
17. Клячкина И. Л. Выбор лекарственных препаратов при продуктивном кашле // Consilium Medicum. 2007; т. 9, № 1.
18. Beeh K. M., Beier J., Esperester A., Paul L. D. Antiinflammatory properties of ambroxol // Eur J Med Res. 2008; 13: 12: 557–562.
19. Зайцев А. А., Моисеев С. В. Бронхоэктазы, не обусловленные муковисцидозом: эпидемиология, диагностика и лечение // Клиническая фармакология и терапия. 2017. Т. 26. № 5. С. 19–24.
20. Balsamo R., Lanata L., Egan C. G. Mucoactive drugs // Eur. Respir. Rev. 2010. Vоl. 19. № 116. P. 127–133.
21. Moretti M. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease // Expert Rev Respir Med. 2007; 1: 307–316.
22. Moretti M. Erdosteine: its relevance in COPD treatment // Expert Opin Drug Metab Toxicol. 2009. Vol. 5. Р. 333–343.
23. Savu S., Mitrea M., Silvestro L., Mancini C. HPLC with on-line mass spectrometry detection applicable to elucidate erdosteine metabolism // Int J Clin Pharm Ther. 2000. Vol. 38. Р. 415–417.
24. Ricevuti G., Nazzone A., Uccelli E. et al. Influence of erdosteine, a mucolytic agent, on amoxicillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis // Thorax. 1988. Vоl. 43. P. 585–590.
25. Braga P. C., Zuccotti T., Dal Sasso M. Bacterial aghesiveness: effects of the SH metabolite of erdosteine (mucoactive drug) plus clarithromycin versus clarithromycin alone // Chemotherapy. 2001. Vоl. 47. P. 208–214.
26. Dal Negro R. Erdosteine: antitussive and anti-inflammatory effects // Lung. 2008; 186: 70–73.
27. Rahman I. Pharmacological antioxidant strategies as therapeutic interventions for COPD // Biochim. Biophys. Acta. 2012. Vоl. 1822. № 5. P. 714–728.
28. Cogo R. Erdosteine: a new therapeutic weapon beyond the PEACE // Trends in Medicine. 2012. Vоl. 12. № 3. P. 133–142.
29. Moretti M., Marchioni C. An overview of erdosteine antioxidant activity in experimental research // Pharmacol Res. 2007; 55: 249–254.
30. Braga P. C., Dal Sasso M., Sala M. T., Gianelle V. Effects of erdosteine and its metabolites on bacterial adhesiveness // Arzneimittelforschung. 1999. Vоl. 49. № 4. P. 344–350.
31. Ricevuti G., Nazzone A., Uccelli E. et al. Influence of erdosteine, a mucolytic agent, on amoxicillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis // Thorax. 1988. Vоl. 43. P. 585–590.
32. Cazzola M., Floriani I., Page C. P. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data // Pulm. Pharmacol. Ther. 2010. Vоl. 23. № 2. P. 135–144.
33. Bisetti A., Mancini C. Mucolytic activity of erdosteine double blind clinical trial vs placebo // Arch. Med. Inter. 1995; 47: 89–97.
34. Bianchi B., Ballabio M., Moretti M. Effects of erdosteine on serum biomarker concentrations at COPD exacerbation // Eur. Respir. J. 2010; 36: 378.
35. Авдеев С. Н. Перспективы применения современных мукоактивных препаратов в терапии пациентов с хронической обструктивной болезнью легких // Пульмонология. 2014. № 2. С. 100–108.
36. Burgel P.-R., Nesme-Meyer P., Chanez P. et al. Cough and spu- tum production are associated with frequent exacerbations and hospitalizations in COPD subjects // Chest. 2009; 135: 975–982.
37. Speizer F. E., Fay M. E., Dockery D. W. et al. Chronic obstructive pulmonary disease mortality in six U. S. cities // Am. Rev. Respir. Dis. 1989; 140 (3): 49–S55.
38. Prescott E., Lange P., Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection // Eur. Respir. J. 1995; 8: 1333–1338.
39. Vestbo J., Prescott E., Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group // Am. J. Respir. Crit. Care Med. 1996; 153: 1530–1535.
40. De Marco R., Accordini S., Cerveri I. et al. Incidence of chron- ic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm // Am. J. Respir. Crit. Care Med. 2007; 175: 32–39.
41. Dal Negro R., Visconti M., Tognella S., Micheletto C. Erdosteine affects eicosanoid production in COPD // Int J Clin Pharmacol Ther. 2011; 49: 41–45.
42. Fioretti M., Bandera M. Prevention of exacerbation in chronic bronchitis patients with erdosteine // Med. Praxis. 1991. Vоl. 12. № 4. P. 219–227.
43. Moretti M., Bottrighi P., Dallari R. et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: The equalife study // Drugs Exp. Clin. Res. 2004, 30: 143–152.
44. Синопальников А. И., Зайцев А. А. Современный взгляд на фармакотерапию обострений хронической обструктивной болезни легких // Лечащий Врач. 2009. № 10. С. 45–49.
45. Dal Negro R., Wedzicha J., Iversen M. et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study // Eur Respir J. 2017; 12; 50 (4).
Review
For citations:
Zaitsev A.A. Mucoactive cough therapy: what is behind the horizon? Lechaschi Vrach. 2018;(10):22. (In Russ.)
Views:
239
JATS XML
Email this article 
